Skip to content
TrialScanner

NCT02837991

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Phase 1TerminatedCLDXLead

Registry record

Lead sponsor
Celldex Therapeutics
Conditions
Renal Cell Carcinoma (RCC); Clear-cell Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Kidney Neoplasms; Metastatic Renal Cell Carcinoma
Primary completion
Nov 16, 2018Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02837991 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.